A notable advance in the treatment of head and neck squamous cell carcinoma (HNSCC) in recent years has been the development of immunotherapy with immune checkpoint inhibitors (ICIs) using anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies. Here, CD274 is linked to head and neck squamous cell carcinoma.